A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

A Randomized Double-blind Multiple-dose Placebo-controlled Trial to Establish the Efficacy of QBX258 (Combination of VAK694 and QAX576) in Asthma That is Inadequately Controlled With Inhaled Corticosteroids and Long Acting Beta Agonists

This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.

Inclusion Criteria:

• Patients with atopic asthma >1 year duration diagnosed according to the GINA guidelines.
• Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 39 kg/m2.
• Asthma which is not adequately controlled on current treatment, as demonstrated by an Asthma Control Questionnaire (ACQ) score of > 1.5.
• FEV1 40 to 90% of predicted.

Exclusion Criteria:

• Diagnosed with COPD as defined by the GOLD guidelines
• Subjects who have had a respiratory tract infection within 4 weeks prior to screening.
• Women of child-bearing potential must use highly effective methods of contraception during dosing and for at least 18 weeks after last study drug administration